Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

Here are some of the largest recent moves: FMR LLC added 1,575,266 shares (+1392.7%) to their portfolio in Q1 2025, for an estimated $83,441,840; WESTFIELD CAPITAL MANAGEMENT CO LP added 1,341,092 ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

“RYTM is a contemporary interpretation of the classic record player, seamlessly blending rhythm and architecture into a modern design,” Paez writes. Components that are boldly displayed on the ...

RYTM’s Next Steps of Development for Bivamelagon. Building on the encouraging data from the phase II study, Rhythm Pharmaceuticals intends to engage with regulatory authorities in the United ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...